By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



1 DNA Way

South San Francisco  California  94080-4990  U.S.A.
Phone: 650-225-1000 Fax: 650-225-6000


Since 2005, Genentech has been expanding its facilities in Oceanside, about 35 miles north of San Diego. Today, the campus spans 60 acres and includes a multi-product, biotech manufacturing and clinical operations complex with six buildings totaling 500,000 square feet. Upon receiving U.S. Food and Drug Administration licensure in 2007, the Oceanside facility added 90,000 liters of capacity that are now approved for the production of Rituxan and Avastin bulk drug substance.

On the Southern California Coast, halfway between Los Angeles and San Diego, Oceanside is a beautiful beachfront community of roughly 200,000 people. As one of Oceanside’s largest employers, Genentech takes great pride in the impact we have on the community, but also in the impact the community has on our employees.

Please view our company video on YouTube:

Connect with us via Social Media:







CEO: Ian T. Clark

CEO: Ed Harrington

Chief Medical Officer: Sandra J. Horning, MD

Chief Compliance Officer: Frederick C. Kentz, III


Please click here for clinical trial information.

Key Statistics

Ownership: Subsidiary

Web Site: Genentech
Employees: 10,000+
Symbol: RHHBY



Company News
Genentech (RHHBY) Will Pass Out More Cash to Researchers to Stand Up to Cancer 5/18/2017 6:48:47 AM
Genentech (RHHBY) To Present New Data On Personalized Medicines And Cancer Immunotherapies At The 2017 ASCO Annual Meeting 5/11/2017 7:05:31 AM
How Genentech (RHHBY) Could Be A New Threat For Biogen (BIIB) 5/10/2017 6:25:44 AM
Genentech (RHHBY)'s Top Cancer Prospect Flunks Phase III Test 5/10/2017 5:34:51 AM
Genentech (RHHBY) Exec Jumps Ship to Become CMO at Gritstone Oncology 5/3/2017 6:22:08 AM
Corvus Pharma Expands CPI-444 Clinical Collaboration With Genentech (RHHBY) 5/2/2017 8:07:02 AM
Genentech (RHHBY) Quietly Shelves Phase II Cancer Contender 4/27/2017 7:50:55 AM
New Data At American Academy of Neurology Reinforce Clinical Benefit Of Genentech (RHHBY)'s OCREVUS (Ocrelizumab) For Relapsing And Primary Progressive Multiple Sclerosis 4/26/2017 7:04:28 AM
Genentech (RHHBY) To Present New Data At AAN Reinforcing Efficacy And Safety Of Newly FDA Approved OCREVUS (Ocrelizumab) In Two Types Of Multiple Sclerosis 4/19/2017 6:36:25 AM
FDA Clears Genentech (RHHBY)'s Lucentis For All Forms Of Diabetic Retinopathy 4/18/2017 7:21:03 AM